Introduction {#Sec1}
============

The global incidence of diabetes has been steadily increasing over the past few decades \[[@CR1]\]. In Japan, the increasing prevalence of diabetes, particularly type 2 diabetes mellitus (T2D), is a major health concern \[[@CR2]\]. Additionally, the prevalence of diabetes in Japan is predicted to further increase over the next decades, mainly due to an aging population \[[@CR2]\].

Poorly controlled diabetes may lead to a number of serious health complications \[[@CR1]\]. Globally, treatment guidelines for T2D (World Health Organization, American Diabetes Association, and European Association for the Study of Diabetes) recommend a patient-centered and stepwise approach to managing glycemic control \[[@CR1], [@CR3]\]. A focus on lifestyle management and diabetes self-management education and support are recommended, alongside metformin, oral antidiabetic and/or injectable medications, and/or basal insulin, as well as consultation with a healthcare provider (HCP) \[[@CR3]\]. Similarly, guidelines for Japanese patients with diabetes recommend patient education regarding diet and exercise, followed by basal insulin therapy for those with inadequate glycemic control despite therapy with oral glucose-lowering medications \[[@CR4]\]. This treatment strategy, however, should vary depending on the disease condition, age, metabolic abnormality, and status of diabetes complications of each patient \[[@CR4]\].

While treatment with insulin is associated with higher rates of achieving adequate glycemic control \[[@CR1], [@CR3]\], initiation of insulin therapy is often delayed due to a variety of physician- and patient-related factors \[[@CR5]\]. Reluctance to initiate insulin treatment, known as 'psychological insulin resistance' (PIR), is common among adults with diabetes, with a recent study reporting 29.9% of insulin-naïve adults with T2D declined insulin treatment after it was recommended by their HCP \[[@CR6]\]. Recent studies revealed a high reluctance in the use of injectable therapies among injection-naïve Japanese patients with T2D, with less than 2% of study participants initially willing to take injectable medicines \[[@CR7], [@CR8]\].

Numerous studies have examined psychological barriers preventing the initiation of insulin therapy in adults \[[@CR5], [@CR9]--[@CR11]\]. PIR encompasses patient-related concerns, including injection anxiety, misconceptions about insulin, concerns about hypoglycemia, and societal attitudes \[[@CR5], [@CR10], [@CR12], [@CR13]\]. Several studies have documented recommendations to address PIR \[[@CR14]--[@CR17]\]; however, there is little research regarding factors or effective strategies that help reluctant patients begin insulin treatment. In addition, although there are reports describing PIR among Japanese diabetic patients \[[@CR18]--[@CR20]\], the evidence is limited.

To further understand the factors associated with reluctant patients initiating insulin, a multinational, noninterventional study (EMOTION) surveyed current insulin-using adults with T2D who were initially reluctant to begin insulin treatment. The EMOTION (Acc[E]{.ul}pting Insulin Treat[M]{.ul}ent for Reluctant Pe[O]{.ul}ple with [T]{.ul}ype 2 D[I]{.ul}abetes Mellitus---a Gl[O]{.ul}bal Study to Ide[N]{.ul}tify Effective Strategies) study was conducted in 3 phases: qualitative interviews (phase 1) with participants and HCPs in 6 countries (Brazil, Canada, Germany, Spain, the United Kingdom, and the United States), quantitative surveys (phase 2), and follow-up interviews (phase 3) with participants in the same 6 countries plus Japan. Phase 2 of EMOTION identified a number of HCP actions and life events (actions/events) that were rated as being the most helpful amongst the total population \[[@CR21]\]. These included efforts to address injection concerns by demonstrating the insulin injection process, explaining the benefits of insulin, and adopting a collaborative communication style. The perceived helpfulness of these actions were, in turn, linked with earlier insulin initiation and greater insulin persistence over time \[[@CR21]\].

We report a Japanese population subanalysis of EMOTION (phase 2). We aim to identify HCP actions/events that may help reluctant insulin users with T2D decide to initiate insulin therapy.

Methods {#Sec2}
=======

The data used in this study were derived from the EMOTION study. EMOTION was conducted in 7 countries: Brazil, Canada, Japan, Germany, Spain, the United Kingdom, and the United States. The study protocol was approved by the Western Institutional Review Board (IRB), Puyallup, Washington, USA, as well as the Nagoya University IRB, Nagoya, Japan. All procedures performed in this study involving human participants were in accordance with the ethical standards of the Western IRB, Puyallup, Washington, USA, and the Nagoya University IRB, Nagoya, Japan, and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. Participants were compensated for their time. The study design has been previously described \[[@CR21]\]. Briefly, qualitative interviews with a total of 29 insulin-using adults with T2D and 29 HCPs across 6 countries (Brazil, Canada, Germany, Spain, the United Kingdom, and the United States) were conducted to inform survey content and design. Phase 2 involved a 30-min quantitative survey, derived from the qualitative interviews, with participants with T2D from these same nations plus Japan. This report focuses on the findings of the quantitative survey in Japanese participants with T2D.

Participants were selected from the market research panels of Survey Sampling International (SSI) and their local partners in Japan. Surveys were translated for Japanese participants by professional linguists from TransPerfect with knowledge of the language, the subject area, and the target audience. Survey participants were compensated for their time.

Eligible participants were adults (≥ 21 years old) with T2D who reported that they were initially not willing to start insulin treatment (i.e., chose "not willing" among the options "not willing," "slightly willing," "moderately willing," or "very willing"). Participants had been diagnosed with T2D at least 1 year before starting basal insulin (self-reported), started basal insulin between 30 days and 3 years before the survey, and had used any insulin regularly for the 30 days before the survey. Subjects were ineligible if they had been diagnosed with any other type of diabetes, had experience with insulin therapy before the initiation of basal insulin therapy, or if they had initiated insulin using a premix product or basal bolus therapy.

Quantitative surveys were administered to eligible participants between December 2016 and August 2017. Participants were given the survey via an online platform. Participants were asked to survey 45 actions and statements that assisted in insulin initiation and to denote whether each action occurred. Actions/events that occurred were then rated for helpfulness on a 4-point Likert scale: 1 = it didn't help at all, 2 = it helped a little, 3 = it helped moderately, 4 = it helped a lot. Other questions in the following key areas were included: participant demographics; disease history; time from initial HCP consult to initiation of insulin; reasons for insulin reluctance; transformative point/person involved in initiation of insulin; role of HCP in initiating insulin; experiences post-insulin initiation satisfaction with treatment; and attitude regarding insulin use. Completed surveys were screened to identify and omit those that were problematic (e.g., surveys which were completed in \< 10 min or had the same responses to all survey items pertaining to HCP messages and actions).

Findings were presented using descriptive summary statistics, which included the number and percentage of participants with specific responses to categorical questions, the means and standard deviations for continuous variables (including age and years since first diabetes diagnosis), and actions/events with Likert-scale responses. The mean level of helpfulness of each item was calculated and rated from the most to the least helpful. Outcomes related to experiences post-insulin initiation were also summarized, including adherence to insulin therapy, experiences related to weight, energy, mood, and hypoglycemia, treatment satisfaction with insulin therapy, and attitude about insulin following insulin initiation.

Results {#Sec3}
=======

Participant Characteristics {#Sec4}
---------------------------

Of the 594 adults who were eligible to participate in phase 2 of the EMOTION study, 99 were from Japan. The mean age of the Japanese participants was 57.7 years \[standard deviation (SD) 9.6\]. Most participants were male (79.8%), and the mean time from initial T2D diagnosis to first insulin use was 12.2 years (SD 7.7). The mean body mass index of Japanese participants was 25.4 kg/m^2^ (SD 3.7). The mean hemoglobin A1c (HbA1c) at the time of insulin initiation was 9.4% (SD 2.0), while the most recent HbA1c was 7.8% (SD 1.2). Baseline participant demographics are presented in Table [1](#Tab1){ref-type="table"}.Table 1Participant characteristicsParameter(*N* = 99)Age, mean (SD)57.7 (9.6)Gender, male, *n* (%)79 (79.8)Years from T2D diagnosis to insulin use, mean (SD)12.2 (7.7)BMI (kg/m^2^)^a^, mean (SD)25.4 (3.7)Prior use of injectable diabetes medications^b^, *n* (%)20 (20.2)HbA1c value prior to insulin initiation^c^ HbA1c, %, mean (SD)9.4 (2.0) HbA1c, mmol/mol, mean (SD)78.8 (22.1)Most recent HbA1c test^c^ HbA1c, %, mean (SD)7.8 (1.2) HbA1c, mmol/mol, mean (SD)61.7 (12.7)Year of insulin initiation (%) 201548.5 201634.3 201714.1*BMI* body mass index, *HbA1c* hemoglobin A1c, *GLP-1* glucagon-like peptide 1, *N/n* number of participants, *T2D* type 2 diabetes mellitus, *SD* standard deviation^a^BMI categories were defined using the World Health Organization's Internal Classification^b^Mainly indicates treatment with GLP-1 receptor agonist, not any insulin therapy^c^Mean HbA1c was calculated among patients who had a test in the past year and knew the test result. HbA1c mmol/mol was converted to % and vice versa according to the HbA1c conversion tables (Sept. 2011) of the New Zealand Society for the Study of Diabetes

Insulin Initiation {#Sec5}
------------------

Participants' thoughts and feelings prior to initiating insulin are outlined in Table [2](#Tab2){ref-type="table"}. Participants were aware that taking insulin would help to maintain good control of blood glucose (76.8%), and that taking insulin would help to improve their health (75.8%). The most common negative thought amongst Japanese participants was that taking insulin meant that their diabetes had become much worse (72.7%). Another common negative thought amongst Japanese participants was that the associated use of insulin meant that they had failed to manage their diabetes (62.6%). Participants also reported being afraid of injecting themselves with a needle (48.5%), and that the insulin recommendation meant that they would be required to take insulin forever (48.5%).Table 2Thoughts and feelings experienced by Japanese patients with T2D before initiating insulin treatmentThoughts and feelings about insulin right before starting insulin regularly for the first timeFrequency^a^\
*n* (%)Taking insulin would help to maintain good control of blood glucose (sugar levels)76 (76.8)Taking insulin would help to improve my health75 (75.8)Taking insulin would mean my diabetes had become much worse72 (72.7)Taking insulin would help to prevent complications of diabetes71 (71.7)Taking insulin would mean that I had failed, that I hadn't done a good enough job taking care of my diabetes62 (62.6)I was afraid of injecting myself with a needle48 (48.5)Taking insulin would mean that I would need to take insulin forever48 (48.5)Taking insulin would mean that I had failed to manage my diabetes with diet and tablets46 (46.5)Taking insulin would mean that my diabetes would become a much more serious condition44 (44.4)Taking insulin would make me more dependent on my doctor43 (43.4)Taking insulin would mean other people would see me as a sick/sicker person42 (42.4)Injecting insulin would be painful41 (41.4)Taking insulin would increase the risk of low blood glucose levels (hypoglycemia)38 (38.4)It would be difficult to inject the right amount of insulin correctly at the right time every day38 (38.4)Managing insulin injections would take a lot of time and energy37 (37.4)Taking insulin would make life less flexible34 (34.3)Taking insulin would help to improve my energy level32 (32.3)Injecting insulin would be embarrassing30 (30.3)Being on insulin would cause family and friends to be more concerned about me29 (29.3)Insulin would cause weight gain28 (28.3)Taking insulin would mean I would have to give up activities I enjoy19 (19.2)Taking insulin might cause serious health problems such as blindness, kidney problems, or amputations14 (14.1)Taking insulin would make it more difficult to fulfill my responsibilities (at home and work)13 (13.1)Taking insulin would mean my health would deteriorate6 (6.1)Taking insulin would cause me to lose my job6 (6.1)^a^Frequency was calculated using responses of 'agree' and 'strongly agree.' Agreement with these statements was categorized as either 'strongly disagree,' 'disagree,' 'neither agree nor disagree,' 'agree,' or 'strongly agree'

Participants' reactions following their HCPs' recommendation to begin insulin, time to insulin initiation, and any insulin discontinuations (for ≥ 7 days) are presented in Table [3](#Tab3){ref-type="table"}. Participants reported being moderately (28.3%) or very surprised (12.1%) by the recommendation to initiate insulin, with 29.3% and 13.1%, respectively, being moderately or very upset. When insulin was recommended for the first time, 40.4% of participants indicated that they were slightly willing to initiate insulin therapy, while 59.6% were not willing at all. Despite this unwillingness, 80.8% of the participants immediately commenced regular insulin therapy upon first recommendation. The number of Japanese participants who reported one or more periods of discontinuing insulin for ≥ 7 days was 8.1%.Table 3Participants' reactions when insulin was first recommended, and their insulin-taking behaviorParticipants' reactions when insulin was first recommended and their insulin-taking behaviorFrequency\
*n* (%)\
(*N* = 99)Level of surprise when HCP first said it was time to take insulin, *n* (%)  Not surprised at all26 (26.3)  Slightly surprised33 (33.3)  Moderately surprised28 (28.3)  Very surprised12 (12.1)Level of being upset when HCP first said it was time to take insulin, *n* (%)  Not upset at all22 (22.2)  Slightly upset35 (35.4)  Moderately upset29 (29.3)  Very upset13 (13.1)Willingness to start insulin when first recommended, *n* (%)  Not willing59 (59.6%)Time between the first recommendation of insulin and the start of regular insulin use, *n* (%)  I started taking it right away80 (80.8)  Less than 1 week1 (1.0)  About 1 or 2 weeks2 (2.0)  bout 1 month4 (4.0)  2--3 months4 (4.0)  More than 1 year8 (8.1)Taking insulin regularly91 (91.9)Stopped insulin for a period of 7 or more days since first starting insulin, *n* (%)8 (8.1) During the first month after I first started taking insulin0 (0.0) 1--3 months after I first started taking insulin2 (25.0) 3--6 months after I first started taking insulin3 (37.5) More than 6 months after I first started taking insulin3 (37.5)*HCP* healthcare provider, *n/N* number of participants

HCP Actions and Life Events Experienced by Japanese Participants {#Sec6}
----------------------------------------------------------------

The most frequently occurring HCP actions experienced by Japanese patients with T2D are displayed in Fig. [1](#Fig1){ref-type="fig"}. Overall, the most common HCP action was the advice that blood glucose levels would improve upon commencing insulin (96.0%). The actions ranked second to fifth in occurrence were 'HCP helped the patient to see how simple it is to inject insulin' (91.9%), 'HCP walked the patient through the process of how to use insulin' (87.9%), 'HCP gave patient leaflets or other reading material about insulin' (85.9%), and 'HCP helped patient to see that an insulin injection wasn't as painful as patient thought it might be' (83.8%).Fig. 1HCP actions and life events most commonly experienced by Japanese participants with T2D.The 12 most common HCP actions experienced by Japanese participants with T2D are shown. Life events were considered, but they were not amongst the actions/events most commonly reported by Japanese participants. *HCP* healthcare provider, *T2D* type 2 diabetes mellitus

The HCP actions/events least commonly experienced by Japanese participants with T2D are displayed in Table S1 of the Electronic supplementary material (ESM), and include 'HCP helped patient to meet other people taking insulin' (8.1%), 'A close friend or family member urged patient to go along with HCP recommendation to start insulin' (12.1%), and 'HCP told patient that he/she could not continue to treat patient if patient refused to start insulin' (14.1%).

Most and Least Helpful HCP Actions and Life Events for Patients with T2D Initiating Insulin Treatment {#Sec7}
-----------------------------------------------------------------------------------------------------

Actions/events that were most helpful in assisting participants to initiate insulin treatment are displayed in Fig. [2](#Fig2){ref-type="fig"}. The most helpful actions/events, reported as helping moderately or a lot, were 'HCP walked patient through the process of exactly how to take insulin' (82.8%, mean level of helpfulness 3.28), 'HCP showed an insulin pen' (79.7%, mean level of helpfulness 3.20), 'HCP helped patient to see how simple it was to inject insulin' (79.1%, mean level of helpfulness 3.19), 'HCP had patient try an injection himself/herself while patient was there in the office' (75.0%, mean level of helpfulness 3.14), and 'HCP gave an injection while patient was in the office' (72.0%, mean level of helpfulness 3.12).Fig. 2HCP actions and life events rated as most helpful to Japanese participants with T2D in deciding whether to initiate insulin therapy.The 12 most helpful HCP actions/events experienced by T2D Japanese participants in deciding whether to initiate insulin therapy are shown. *HCP* healthcare provider, *T2D* type 2 diabetes mellitus. ^a^Mean level of helpfulness based on a 4-point scale; 1 = it didn't help at all, 2 = it helped a little, 3 = it helped moderately, 4 = it helped a lot

Actions/events that were least helpful in assisting participants initiate insulin treatment are displayed in Table S1 of the ESM. The least helpful actions/events according to Japanese participants were 'HCP helped patient to meet other people who had already been taking insulin' (25.0%, mean level of helpfulness 2.13), 'HCP referred patient to a class to help learn more about insulin' (31.6%, mean level of helpfulness 2.26), and 'Patient sought out information about insulin and realized that insulin might not be as bad as first thought' (40.0%, mean level of helpfulness 2.35).

Discussion {#Sec8}
==========

Possible consequences of delayed insulin use for patients with T2D include serious health complications such as heart disease, stroke, kidney failure, vision loss, and nerve damage \[[@CR1]\]. It is therefore imperative that HCPs understand psychological insulin resistance in patients so that adequate measures can be taken to reduce the delay in insulin initiation.

We report a Japanese subpopulation analysis of EMOTION, a multinational survey of current insulin-using adults with T2D. Approximately 40% of all Japanese participants reported being moderately or very surprised with the recommendation to commence insulin, with approximately 42% being moderately or very upset. Despite an initial unwillingness to initiate insulin therapy, approximately 80% of Japanese participants initiated insulin treatment immediately. Notably, the majority of the participants continued to use insulin once they initiated it. This high uptake rate may reflect Japanese participants' trust in their HCPs, a trait associated with increased insulin adherence and reduced diabetes-related stress \[[@CR22]\].

Psychosocial factors affecting insulin usage appear to be common among diabetic patients worldwide \[[@CR13]\], and educational programs related to insulin initiation differ between Japanese and non-Japanese physicians \[[@CR23]\]. Our results indicate that HCP actions are significantly associated with a patient's decision to initiate insulin. We identify a number of HCP actions/events deemed to be the most and least helpful for initiating insulin among reluctant Japanese adults with T2D. Namely, HCP actions that provided practical demonstrations on how to use insulin were the most helpful. Reassurance concerning pain of injection, explanations regarding blood glucose numbers and future health, encouragement to make contact in case of any problems, and occurrence of a positive life event were also rated highly by Japanese participants as being helpful in deciding to start insulin treatment. In addition, some actions occurred less frequently but were considered very useful by Japanese participants. In particular, 'HCP gave an injection while patient was in the office' was not an action performed by many HCPs (25.3%), but was rated as helping moderately or a lot by 72.0% of participants. Similarly, 'Patient talked with someone who was taking insulin and realized it might not be as bad as patient thought' did not occur often (16.2%), but when it did occur, 62.5% of participants found this helped moderately or a lot.

HCP actions and life events rated as least helpful were those that referred the patient elsewhere, including HCP referral to educational classes and meeting other patients. Additionally, communication style may be important for Japanese patients. For example, 'HCP warned patient that he/she was likely to develop complications if the patient didn't get started with insulin to control his/her diabetes' was only helpful for approximately half of participants (49.2%). Similarly, 'HCP warned patient that he/she could not be responsible for what might happen if he/she did not start insulin soon' was only helpful to 39.1% of Japanese participants.

Recent studies have examined reluctance to initiate insulin treatment in various populations. It has been documented that patients who were nonadherent to insulin regimens frequently felt that their HCP did not adequately explain the benefits and risks of insulin treatment \[[@CR12]\]. Perceived physician inattention and lack of engagement as well as diabetes-related distress affect insulin adherence and glycemic control \[[@CR24]\]. Many factors, including information, adequate counseling, and positive role models, have been found to influence PIR \[[@CR25]\]. A multinational study that included Japan examined experiences during and after insulin initiation and discovered that patients who were classified as treatment 'interrupters' or 'discontinuers' were more likely to have concerns and challenges during the initiation process \[[@CR26]\]. These patients were also less likely to exhibit improvements in glycemic control compared to patients classified as treatment 'continuers' \[[@CR26]\]. In addition, a recent multicenter Japanese study concluded that educating patients about the benefits of insulin therapy may help reluctant insulin users to initiate therapy, and that practical support may assist current insulin users in maintaining therapy \[[@CR20]\]. Indeed, our results relating to the helpfulness of HCP actions support these findings and highlight the important role that HCPs play in preventing and/or overcoming PIR amongst patients with T2D.

The Diabetes Attitudes, Wishes and Needs (DAWN2) survey was a global initiative aimed at assessing diabetes care and management among people with diabetes, as well as their HCPs and family members. DAWN2 was conducted in 17 countries, including Japan \[[@CR23], [@CR27]\]. In all countries surveyed, DAWN2 revealed that diabetes is a significant physical and psychological burden for many individuals with diabetes \[[@CR23]\]. Specifically, DAWN2 reported depression (13.8%), diabetes-related distress (44.6%), poor or very poor quality of life (12.2%), a negative impact on relationships (20.5%) and physical health (62.2%), and medication interference in daily life (approximately 40%) \[[@CR23]\]. Many factors may have influenced the findings from DAWN2, such as socioeconomic and cultural factors as well as differences in healthcare systems between countries. Indeed, in our analysis, there are notable differences between Japanese and Caucasian participants from the global EMOTION analysis. For example, differences in the level of full-time employment (51.5% Japan vs 35.0% US) and education (participants who completed high school: 42.4% Japan vs 18.3% US) were observed. Primary care physicians in Japan were more likely to be involved in assisting patients with initiating insulin compared to the overall EMOTION population (76.8% Japan vs 37.4% overall population), for whom this task was also likely to be performed by endocrinologists (12.6%) and diabetes nurse specialists (14.0%). Hence, country-specific analyses are warranted.

Diabetes-related distress, known as the emotional burden of and reaction to managing a chronic illness, is associated with a higher rate of diabetes-related complications \[[@CR23], [@CR28], [@CR29]\]. A positive educational experience and support from HCPs at the time of insulin recommendation may be pivotal to maintaining adequate glycemic control and the long-term health of patients with T2D. In fact, a large retrospective cohort study found that a substantial proportion of people continue with poor glycemic control for several years before initiating intensification with oral antidiabetic medications and insulin \[[@CR30]\]. Diabetes health-coaching consisting of goal-setting, education, and individualized and follow-up care have also been effective strategies to improve glycemic control, as demonstrated in a recent meta-analysis which concluded that diabetes health-coaching resulted in a statistically significant reduction in HbA1c levels (0.32%) \[[@CR31]\]. Physician empathy is also noted as contributing to improved HbA1c outcomes \[[@CR32]\], and practical strategies that HCPs can utilize to assist their patients to overcome emotional barriers may be warranted (e.g., the use of mnemonics) \[[@CR33]\]. Practical diabetes health-coaching, along with routine diabetes care, supports our findings amongst Japanese participants, and may be a valuable tool to help motivate T2D patients to initiate and maintain insulin treatment.

This study provides valuable data regarding the experiences of Japanese participants diagnosed with T2D. We identify HCP actions and life events that were helpful in initiating insulin treatment. Our results agree with recently described results of a stepwise approach to diabetes and insulin education \[[@CR17]\], which encompassed problem-solving, patient education, and physician enquiries about patient feelings and fears.

The strength in our analysis lies in the description of helpful (and less helpful) HCP actions rated by Japanese participants with T2D; data which are, at present, limited in this population. Limitations relating to the study design, however, should be noted. Firstly, the majority of survey respondents were recruited from online panels of individuals who had volunteered to participate in studies. These participants, therefore, may be more involved in their own diabetes management in comparison with typical patients. Perceptions regarding helpful PIR actions in these volunteers may not be indicative of the perceptions of the broader population. Secondly, the majority of Japanese survey participants were male and responses may vary with increased female participation. Thirdly, survey responses may be due to recall bias, with participants having initiated insulin between 2015 and 2017. Finally, the retrospective nature of the study should raise some caution: self-reported data may not be accurate and could potentially be subject to bias.

Further studies amongst this patient population are warranted and may further assist HCPs in providing optimal care for Japanese patients with T2D. Other factors that may affect PIR in Japanese patients, such as age, socioeconomic status, and mental health, also warrant further investigation.

Conclusion {#Sec9}
==========

Our findings suggest that a tailored approach in which HCPs explain the insulin injection process from patients' perspectives is beneficial for reluctant Japanese insulin users. This study provides important information on actions that can be used by HCPs to assist Japanese adults with T2D who are reluctant insulin users in overcoming PIR. More generally, the findings from this survey of Japanese adults with T2D, who were initially reluctant to begin insulin treatment, suggest potentially useful clinical interventions for helping patients overcome PIR, a critical step towards designing comprehensive clinical recommendations for HCPs.
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